期刊
HEPATOLOGY
卷 63, 期 1, 页码 217-232出版社
WILEY
DOI: 10.1002/hep.28274
关键词
-
资金
- Biogen, Inc.
- Stomedix, Inc.
- Department of Medicine, Beth Israel Deaconess Medical Center
- career development award from The First Affiliated Hospital of Sun Yat-sen University
- National Natural Science Foundation of China [81301842]
- Pearl River ST Nova Program [2014J2200087]
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER
Integrin v6 is rapidly up-regulated on cells of epithelial lineage during tissue injury, where one of its primary functions is activation of latent transforming growth factor beta 1 (TGF1). In human liver cirrhosis, v6 is overexpressed by cells comprising the ductular reaction, and its inhibition suppresses experimental biliary fibrosis in rodents. Here, we show that v6 is expressed on the actively proliferating subset of hepatic progenitor cells and is required for their progenitor function in vivo and in vitro through integrin v6-dependent TGF1 activation. Freshly isolated v6(+) liver cells demonstrate clonogenic potential and differentiate into cholangiocytes and functional hepatocytes in vitro, whereas colony formation by epithelial cell adhesion molecule-positive progenitor cells is blocked by v6-neutralizing antibody and in integrin beta 6-deficient cells. Inhibition of progenitors by anti-v6 antibody is recapitulated by TGF1 neutralization and rescued by addition of bioactive TGF1. Genetic disruption or selective targeting of v6 with 3G9 antibody potently inhibits progenitor cell responses in mouse models of chronic biliary injury and protects from liver fibrosis and tumorigenesis, two conditions clinically associated with exacerbated ductular reaction. Conclusion: These results suggest that v6 is a promising target for chronic fibrotic liver diseases and associated cancers. (Hepatology 2016;63:217-232)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据